InnerMost Launches to Evolve Psychedelic Therapy - Advancing Treatment, Access, and Knowledge in the Field

Uniting FDA-authorized trials, ketamine and Spravato therapy, therapist training, and community education under one roof, InnerMost brings a vital new resource, contributing to the field globally

NEW YORK, NY / ACCESS Newswire / November 21, 2025 / InnerMost PBC, New York City's new psychedelic-assisted therapy center dedicated to accessible care, practitioner training, FDA-authorized clinical trials, and community building, is officially open.

A public benefit corporation, InnerMost provides accessible ketamine and Spravato therapy, is an FDA-trial site that trains psychedelic-assisted therapists, and builds community amongst clinicians in this paradigm-shifting field.

With mental health needs at an all-time high, and uncertainty across politics and research, its launch introduces a hub for evidence-based psychedelic care-supporting New Yorkers while advancing access and progress globally. New hope emerges as the mainstream embraces new evidence-based approaches that expand what's possible in mental health care.

Leading conversations about psychedelic therapy's past, present and future is Casey Paleos, MD, (CV) Co-Founder & Chief Medical Officer, board-certified psychiatrist and researcher with 15+ years in psychedelic-assisted therapy. As figures like Rick Doblin pass the baton, they sing praises about his body of work and vision:

  • Principal Investigator, MAPS MDMA therapy for PTSD Studies

  • Therapist, NYU Psilocybin Cancer Anxiety Study

  • Co-Founder, Nautilus Sanctuary

  • Founding Board Member, International Alliance of MDMA Practitioners

  • Presenter, "Understanding Ketamine" Workshop, Psychotherapy Networker conference, Washington, D.C.

  • Co-Author of "Inner-Directed Therapy in MDMA-Assisted Psychotherapy," newly released commentary on the MDMA debate in the American Journal of Psychiatry

WHY INNERMOST IS DIFFERENT:

  • Research:FDA-authorized clinical trial site, including ongoing MDMA research and more TBA.

  • Treatment: Integration of psychotherapy with ketamine, Spravato, and future integrative mental health modalities.

  • Training: Practicum training, mentorship and clinical supervision.

  • Education & Community: Public programming, podcasts, panels, and partnerships.

  • Accessibility: Public benefit corporation whose mission is to eliminate socioeconomic barriers to accessing psychedelic therapies.

VISUALS:

  • First look at InnerMost's space and design.

  • Interviews with Dr. Paleos and team.

  • Photo and video opportunities.

Now open to the public by appointment at innermost.one, media are invited to schedule private tours of InnerMost.

MEDIA CONTACT: Marissa Feinberg | marissa@triplebottomwhy.com | 917-494-5041

SOURCE: InnerMost



View the original press release on ACCESS Newswire

Recent Quotes

View More
Symbol Price Change (%)
AMZN  198.79
-0.81 (-0.41%)
AAPL  255.78
-5.95 (-2.27%)
AMD  207.32
+1.38 (0.67%)
BAC  52.55
+0.03 (0.06%)
GOOG  306.02
-3.35 (-1.08%)
META  639.77
-10.04 (-1.55%)
MSFT  401.32
-0.52 (-0.13%)
NVDA  182.81
-4.13 (-2.21%)
ORCL  160.14
+3.66 (2.34%)
TSLA  417.44
+0.37 (0.09%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.